Stock listing
OTC:ANEB Anebulo Pharmaceuticals, Inc. Stock
Home listing (OTC) of Anebulo Pharmaceuticals, Inc.
Follow Anebulo Pharmaceuticals, Inc. into a list and get an email when it puts out news.
Share price · OTC:ANEB
$0.26 USD -0.02 (-7.1%)
Close on Nov 20, 2026
- Day range
- $0.26 – $0.26 USDNov 20, 2026
- Volume
- 100 sharesNov 20, 2026
- Market cap
- $10.60M USDAt the close on Nov 20, 2026 · price × 40.78M shares outstanding
- 52-week range
- $0.0010 – $2.49 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $118 USDMedian day 100 shares · 4 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| OTC:ANEB · Home | $0.26 USD | -0.02 (-7.1%) | 100 | $0.26 | $0.26 | $0.26 | $0.28 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:ANEB · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.26 | -0.02 | -7.1% | $0.26 | $0.26 | $0.26 | 100 | |
| $0.28 | 0.00 | 0.0% | $0.28 | $0.28 | $0.28 | 100 | |
| $0.28 | +0.02 | +7.7% | $0.28 | $0.28 | $0.28 | 100 | |
| $0.26 | -0.02 | -7.1% | $0.26 | $0.26 | $0.26 | 106 | |
| $0.28 | +0.02 | +7.7% | $0.28 | $0.28 | $0.28 | 100 | |
| $0.26 | -0.003 | -1.0% | $0.26 | $0.26 | $0.26 | 100 | |
| $0.263 | -0.027 | -9.4% | $0.263 | $0.263 | $0.263 | 100 | |
| $0.29 | +0.015 | +5.5% | $0.29 | $0.29 | $0.29 | 103 | |
| $0.275 | +0.015 | +5.8% | $0.275 | $0.275 | $0.275 | 100 | |
| $0.26 | 0.00 | 0.0% | $0.26 | $0.26 | $0.0010 | 18,400 | |
| $0.26 | 0.00 | 0.0% | $0.26 | $0.26 | $0.26 | 100 | |
| $0.26 | 0.00 | 0.0% | $0.26 | $0.26 | $0.26 | 100 | |
| $0.26 | +0.018 | +7.5% | $0.26 | $0.26 | $0.26 | 100 | |
| $0.242 | -0.018 | -7.0% | $0.242 | $0.242 | $0.242 | 123 | |
| $0.26 | -0.015 | -5.5% | $0.26 | $0.26 | $0.26 | 100 | |
| $0.275 | +0.015 | +5.8% | $0.275 | $0.275 | $0.275 | 100 | |
| $0.26 | -0.015 | -5.5% | $0.26 | $0.26 | $0.26 | 100 | |
| $0.275 | -0.015 | -5.2% | $0.275 | $0.275 | $0.275 | 100 | |
| $0.29 | 0.00 | 0.0% | $0.29 | $0.29 | $0.29 | 100 | |
| $0.29 | 0.00 | 0.0% | $0.29 | $0.29 | $0.29 | 100 | |
| $0.29 | -0.005 | -1.7% | $0.29 | $0.29 | $0.29 | 100 | |
| $0.295 | -0.015 | -4.8% | $0.295 | $0.295 | $0.295 | 100 | |
| $0.31 | 0.00 | 0.0% | $0.31 | $0.31 | $0.31 | 100 | |
| $0.31 | -0.005 | -1.6% | $0.31 | $0.31 | $0.31 | 100 | |
| $0.315 | 0.00 | 0.0% | $0.315 | $0.315 | $0.315 | 100 | |
| $0.315 | 0.00 | 0.0% | $0.315 | $0.315 | $0.315 | 100 | |
| $0.315 | +0.005 | +1.6% | $0.315 | $0.315 | $0.315 | 100 | |
| $0.31 | -0.01 | -3.1% | $0.31 | $0.31 | $0.31 | 100 | |
| $0.32 | 0.00 | 0.0% | $0.32 | $0.32 | $0.32 | 100 | |
| $0.32 | 0.00 | 0.0% | $0.32 | $0.32 | $0.32 | 102 | |
| $0.32 | 0.00 | 0.0% | $0.32 | $0.32 | $0.32 | 113 | |
| $0.32 | 0.00 | 0.0% | $0.32 | $0.32 | $0.32 | 100 | |
| $0.32 | 0.00 | 0.0% | $0.32 | $0.32 | $0.32 | 106 | |
| $0.32 | 0.00 | 0.0% | $0.32 | $0.32 | $0.32 | 100 | |
| $0.32 | 0.00 | 0.0% | $0.32 | $0.32 | $0.32 | 100 | |
| $0.32 | -0.005 | -1.5% | $0.32 | $0.32 | $0.32 | 100 | |
| $0.325 | 0.00 | 0.0% | $0.30 | $0.325 | $0.30 | 374 | |
| $0.325 | +0.025 | +8.3% | $0.325 | $0.325 | $0.325 | 200 | |
| $0.30 | -0.015 | -4.8% | $0.30 | $0.30 | $0.30 | 2,200 | |
| $0.315 | 0.00 | 0.0% | $0.315 | $0.315 | $0.315 | 0 | |
| $0.315 | +0.015 | +5.0% | $0.315 | $0.315 | $0.315 | 114 | |
| $0.30 | -0.034 | -10.2% | $0.30 | $0.30 | $0.30 | 100 | |
| $0.334 | -0.026 | -7.2% | $0.334 | $0.334 | $0.334 | 100 | |
| $0.36 | 0.00 | 0.0% | $0.36 | $0.36 | $0.36 | 100 | |
| $0.36 | +0.028 | +8.6% | $0.011 | $0.36 | $0.011 | 200 | |
| $0.332 | 0.00 | 0.0% | $0.332 | $0.332 | $0.332 | 100 | |
| $0.332 | 0.00 | 0.0% | $0.332 | $0.332 | $0.332 | 100 | |
| $0.332 | -0.026 | -7.2% | $0.332 | $0.332 | $0.332 | 100 | |
| $0.357 | -0.033 | -8.4% | $0.357 | $0.357 | $0.357 | 100 | |
| $0.39 | +0.031 | +8.6% | $0.39 | $0.39 | $0.39 | 100 | |
| $0.359 | -0.031 | -7.9% | $0.359 | $0.359 | $0.359 | 100 | |
| $0.39 | +0.09 | +30.0% | $0.39 | $0.39 | $0.39 | 100 | |
| $0.30 | -0.015 | -4.8% | $0.30 | $0.30 | $0.30 | 100 | |
| $0.315 | 0.00 | 0.0% | $0.315 | $0.315 | $0.315 | 0 | |
| $0.315 | 0.00 | 0.0% | $0.315 | $0.315 | $0.315 | 0 | |
| $0.315 | -0.015 | -4.5% | $0.315 | $0.315 | $0.315 | 100 | |
| $0.33 | 0.00 | 0.0% | $0.33 | $0.33 | $0.33 | 100 | |
| $0.33 | 0.00 | 0.0% | $0.33 | $0.33 | $0.33 | 100 | |
| $0.33 | +0.017 | +5.4% | $0.33 | $0.33 | $0.33 | 100 | |
| $0.313 | -0.017 | -5.2% | $0.313 | $0.313 | $0.313 | 100 | |
| $0.33 | -0.02 | -5.7% | $0.33 | $0.33 | $0.33 | 100 | |
| $0.35 | 0.00 | 0.0% | $0.35 | $0.35 | $0.35 | 0 |
- Ticker
- OTC:ANEB
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
Anebulo Pharmaceuticals, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- Decks
- 5 decks · latest October 2024
Where Anebulo Pharmaceuticals, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| OTC:ANEB · Home listing · This page | OTC | United States | USD |
| LS Exchange:A3CM1D | LS Exchange | Germany | EUR |
Valuation
Price/book 1.3× against a median of 1.1×: 6th lowest of 8 Biotechnology companies shown. Statements: Year to Jun 30, 2025 · balance Dec 31, 2025 · price Nov 20, 2026
- Enterprise value
- $1.56M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- -0.01
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. · OTC:ANEB | US$10.60M | US$1.56M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | -0.01 |
| Dyadic International, Inc. · NASDAQ:DYAI | US$11.51M | US$12.03M | n/a | 3.9× | n/a | n/a | −226.9% | n/a | 1.12 |
| Psyence Biomedical Ltd. · NASDAQ:PBM | US$11.33M | US$4.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.90 |
| Medicenna Therapeutics Corp. · TSX:MDNA | US$11.26M | US$7.37M | n/a | n/a | n/a | 9.7× | n/a | 0.1× | 1.36 |
| Miro Sciences Ltd · ASX:MSX | US$11.09M | US$8.03M | n/a | n/a | n/a | 1.1× | n/a | 0.0× | n/a |
| Shaperon Inc. · KRX:378800 | US$11.05M | −US$8.11M | n/a | −33.9× | n/a | 0.8× | n/a | 0.0× | n/a |
| Fractyl Health, Inc. · NASDAQ:GUTS | US$10.88M | −US$20.64M | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| TME Pharma N.V. · EURONEXT:ALTME | US$10.76M | US$12.80M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PharmAla Biotech Holdings, Inc. · CSE:MDMA | US$10.76M | US$10.59M | n/a | 12.0× | n/a | 7.9× | −126.9% | 0.0× | 0.38 |
| IRLAB Therapeutics AB Class A · OMXSTO:IRLAB_A | US$10.60M | US$9.62M | n/a | 1.2× | n/a | 1.1× | −67.9% | 0.3× | n/a |
| Ceryvyn Therapeutics Limited · ASX:CYV | US$9.96M | −US$9.91M | 0.1× | −14,971× | n/a | 0.5× | n/a | 0.0× | n/a |
| Median of the others | US$10.96M | US$7.70M | 0.1× | 1.2× | 1.1× | −126.9% | 0.0× | 1.12 |
Forecasts
1 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 3.00 USD · Analysts' mean
- EPS, year to Jun 2026
- -0.48 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Richie Cunningham | Chief Executive Officer |
| Daniel George | Acting Chief Financial Officer |
| Kenneth Cundy | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Joseph F. Lawler | Chairman |
| Areta Kupchyk | Board Member |
| Aron English | Board Member |
| Jason Aryeh | Board Member |
| Kenneth Lin | Board Member |
| Nat Calloway | Board Member |
| Richie Cunningham | Chief Executive Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | May 7, 2026 | +6.4% |
| Q2 2026 | Feb 12, 2026 | +0.9% |
| Q1 2026 | Nov 13, 2025 · After close | −3.8% |
| Q4 2025 | Sep 29, 2025 | +4.2% |
| Q3 2025 | May 13, 2025 · After close | +0.5% |
| Q2 2025 | Feb 14, 2025 · After close | +9.8% |
| Q1 2025 | Nov 13, 2024 · After close | −1.9% |
| Q4 2024 | Sep 25, 2024 · After close | +6.0% |
| Q3 2024 | May 15, 2024 · After close | −6.4% |
| Q2 2024 | Feb 13, 2024 · After close | +5.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Nov 14, 2023 · After close | +5.2% |
| Q4 2023 | Sep 20, 2023 · After close | −0.3% |
| Q3 2023 | May 11, 2023 · After close | 0.0% |
| Q2 2023 | Feb 10, 2023 · Before open | +3.8% |
| Q1 2023 | Nov 10, 2022 · Before open | −2.8% |
| Q4 2022 | Sep 9, 2022 · Before open | −3.5% |
| Q3 2022 | May 11, 2022 · After close | −2.9% |
| Q2 2022 | Feb 10, 2022 · After close | −1.3% |
| Q1 2022 | Nov 12, 2021 · Before open | −2.0% |
| Q4 2021 | Sep 22, 2021 · After close | 0.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2024) | Investor deck | 21 slides | October 2024 |
| Investor Presentation (January 2023) | Investor deck | 33 slides | Jan 9, 2023 |
| Investor Day (September 2022) | Investor day | 53 slides | Sep 26, 2022 |
| Technical Presentation (July 2022) | Technical | 14 slides | Jul 5, 2022 |
| IPO Roadshow (April 2021) | IPO roadshow | 26 slides | Apr 26, 2021 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and development | 4.30M | 3.55M | 5.60M | 2.96M | 2.27M | 150.0K |
| Selling, general and administrative | 4.92M | 4.75M | 6.18M | 3.87M | 1.34M | 140.1K |
| Operating income | -9.22M | -8.31M | -11.8M | -6.83M | -3.61M | -173.4K |
| Depreciation and amortization | 382.0K | 151.2K | 11.8K | 6.83M | 3.61M | 1.04M |
| EBITDA | -8.84M | -8.16M | -11.8M | -174 | 0 | 866.8K |
| Interest expense | 400.0K | 200.0K | 0 | 7.33K | 11.8K | 1.29K |
| Income before tax | -8.48M | -8.20M | -11.7M | -6.83M | -3.61M | -174.6K |
| Income tax | -104.2K | -12.9K | 10.7K | -1.04K | ||
| Net income | -8.48M | -8.20M | -11.7M | -6.83M | -30.3M | -174.6K |
| Earnings per share, basic | -0.25 | -0.32 | -0.47 | 0.29 | -2.83 | -0.01 |
| Earnings per share, diluted | -0.25 | -0.32 | -0.47 | 0.29 | -2.83 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 11.6M | 3.09M | 11.2M | 14.5M | 20.0M | 3.02M |
| Receivables | 73.2K | 3.50K | ||||
| Inventory | -4 | |||||
| Current assets | 12.0M | 3.51M | 11.7M | 15.6M | 21.7M | 3.03M |
| Total assets | 12.1M | 4.07M | 11.7M | 15.6M | 21.7M | 3.03M |
| Accounts payable | 224.2K | 156.4K | 534.5K | 380.8K | 110.0K | 0 |
| Current liabilities | 224.2K | 260.6K | 1.07M | 512.5K | 241.6K | 223.9K |
| Total debt | 201.3K | |||||
| Total liabilities | 487.7K | 260.6K | 1.07M | 512.5K | 241.6K | 223.9K |
| Shareholders' equity | 11.7M | 3.81M | 10.6M | 15.1M | 21.4M | 2.80M |
| Shares outstanding | 41.1M | 25.9M | 25.6M | 23.3M | 23.3M | 23.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -6.35M | -8.09M | -9.68M | -5.44M | -4.87M | -150.8K |
| Capital spending | -3 | -1 | 0 | -4 | 0 | -2 |
| Free cash flow | -6.35M | -8.09M | -9.68M | -5.44M | -4.87M | -150.8K |
| Cash from financing | 14.9M | -62.4K | 6.38M | 6.38M | 21.8M | 3.18M |
| Dividends paid | -8.21M | |||||
| Share buybacks | 8.21M | 3.00M | ||||
| Change in cash | 8.53M | -8.15M | -3.30M | -5.44M | 17.0M | 3.02M |
Cap table
Built by 6ix from Anebulo Pharmaceuticals, Inc.’s releases
- Common shares
- 40,784,731
- Fully diluted
- 40,784,731
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 40,784,731 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 40,784,731 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jason M. Aryeh Other companies: Lifecore Biomedical, Inc. (Director · Since at least Aug 15, 2024); Orchestra BioMed Holdings, Inc. (Director · Since at least Jan 26, 2023); Ligand Pharmaceuticals Incorporated (Director · Since at least May 30, 2007); Immunomedics Inc (Director · Jan 8, 2017 – Jan 8, 2017 · Past); Aralez Pharmaceuticals Inc (Director · Feb 5, 2016 – May 19, 2017 · Past); Novelion Therapeutics Inc (Director · Jun 4, 2012 – May 15, 2017 · Past); Myrexis Inc (Director · Oct 19, 2011 – Jun 18, 2012 · Past); Vaxart, Inc. (Director · May 18, 2007 – May 25, 2011 · Past) | Board Member · Since at least May 6, 2021 |
| Sandra A Gardiner Other companies: Adagio Medical Holdings, Inc (Director · Since at least Jul 31, 2024); Kronos Bio Inc (Interim CFO · Sep 15, 2023 – Sep 15, 2023 · Past); Nektar Therapeutics (Chief Financial Officer · Apr 17, 2023 – Apr 17, 2023 · Past); Lucira Health Inc (Director · Feb 4, 2021 – Jun 1, 2022 · Past); Pulse Biosciences, Inc (CFO & EVP Admin. and Finance · Dec 9, 2020 – Dec 14, 2021 · Past) | Acting Chief Financial Officer · Mar 2, 2023 – Mar 2, 2023 · Past |
| Aron R. English Other companies: Stoneridge, Inc. (Director · Since at least Feb 26, 2026); Dirtt Environmental Solutions Ltd (Director · Since at least Jun 30, 2022) | Board Member · Since at least May 6, 2021 |
| Daniel George Other companies: Adagio Medical Holdings, Inc (Interim CFO · Apr 17, 2025 – Apr 17, 2025 · Past) | Acting Chief Financial Officer · Since at least Nov 5, 2026 |
| Richard Anthony Cunningham Other companies: Tyme Technologies Inc (Chief Executive Officer · Apr 25, 2022 – Sep 16, 2022 · Past) | Chief Executive Officer, Director · Oct 6, 2023 – Apr 4, 2025 · Past |
| Areta Kupchyk | Board Member · Since at least May 6, 2021 |
| Bimal Shah | Since at least Nov 5, 2026 |
| Joseph F. Lawler | Chairman · Since at least Nov 5, 2026 |
| Kenneth Cundy | Chief Scientific Officer · Since at least Apr 4, 2025 |
| Kenneth Lin | Board Member · Since at least Nov 5, 2026 |
All 13 people
| Person | Seat |
|---|---|
| Nat Calloway | Board Member · Since at least Nov 5, 2026 |
| Richie Cunningham | Chief Executive Officer · Since at least Nov 5, 2026 |
| Simon Allen | Chief Executive Officer, Director · Feb 1, 2022 – Dec 9, 2022 · Past |
Log in to ask 6ix AI your own questions about Anebulo Pharmaceuticals, Inc.